Sentences with word «lymphoblastic»

Researchers say their study results for the first time «clearly establish CXCR4 signaling as essential for T - cell acute lymphoblastic leukemia cell growth and disease progression.»

BAFF Levels Are Elevated in Paediatric Patients With Acute Lymphoblastic Leukaemia Compared to Other B - Lineage Neoplasms

A single infusion of the anti-CD19 chimeric antigen receptor T - cell therapy tisagenlecleucel produced durable remissions in pediatric and young adult patients with relapsed or refractory B - cell acute lymphoblastic lymphoma.

Lymphoma was present in 46 of 50, small cell neoplasia in 39, lymphoblastic neoplasia in 7, mast cell disease in 3, and adenocarcinoma in 1.

A group of researchers at the Baylor College of Medicine has published the results of a study in the journal PLoS ONE demonstrating that a concentrated form of the compound sulforaphane found in broccoli and other cruciferous vegetables has been shown to reduce the number of acute lymphoblastic leukemia cells in a lab setting.

The genetic basis of early T - cell precursor acute lymphoblastic leukaemia Nature, 481 (7380), 157 - 163 DOI: 10.1038 / nature10725

I just lost my 19momth old male bullmastiff to lymphoblastic lymphoma!

Besponsa is approved for adults with hard - to - treat or recurring forms of B - cell precursor acute lymphoblastic leukemia (ALL), which nearly 6,000 Americans are diagnosed with each year.

The therapy from Novartis, called Kymriah (tisagenlecleucel), produced an 83 % remission rate in clinical trials for children and young adults afflicted by a blood cancer called acute lymphoblastic leukemia.

Novartis» experimental product, CTL019, is being recommended for children and young adults aged 3 to 25 who have hard - to - treat (or recurring) forms of the rare blood cancer B - cell acute lymphoblastic leukemia (ALL).

In March, the U.S. Food and Drug Administration (FDA) approved BLINCYTO for the treatment of adults and children with B - cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1 percent.

The company announced during the American Society of Hematology (ASH) annual meeting over the weekend that it's prepared to file for FDA approval of CTL019 in early 2017 after promising phase 2 clinical trials showing that patients with the blood cancer B - cell acute lymphoblastic leukemia achieved a significant 82 % complete remission rate after being injected with the drug.

The former produced a complete response (meaning all visible signs of the cancer had disappeared) in 75 % of difficult - to - treat acute lymphoblastic leukemia patients and even stronger results (90 % complete response) in those who were very early in their disease.

The rest comes from its portfolio of hematology and oncology drugs, including Vyxeos for acute myeloid leukemia and Erwinaze for acute lymphoblastic leukemia.

Juno Therapeutics has halted development of JCAR015, its lead chimeric antigen receptor (CAR) T - cell cancer immunotherapy indicated for adults with relapsed / refractory B - cell acute lymphoblastic leukemia (ALL), nearly 4 months after placing a Phase II trial of the candidate on its second clinical hold following two additional patient deaths.

The clinical hold pushes back Juno's earlier plans to pursue FDA approval next year for JCAR015, a CD19 - directed chimeric antigen receptor technology (CAR - T) product candidate that has been under study in ROCKET in adult patients with relapsed or refractory B - cell acute lymphoblastic leukemia.

Juno Therapeutics will resume its Phase II ROCKET clinical trial of its acute lymphoblastic leukemia candidate JCAR015 following the FDA's lifting of a partial clinical hold imposed last week following the deaths of three patients.

The drug, which was first approved last August for patients under 25 with B - cell precursor acute lymphoblastic leukemia, is now OK» ed to treat large B - cell lymphoma.

For the second time in 5 months, Juno Therapeutics has put a clinical hold on a Phase II trial of JCAR015 in adult patients with relapsed or refractory B - cell acute lymphoblastic leukemia due to patient deaths.

Juno Therapeutics is seeking to change the protocol for the Phase II ROCKET clinical trial of its acute lymphoblastic leukemia candidate JCAR015, which the FDA has placed on clinical hold following the deaths of three patients, two of them last week.

The early approval — about a month ahead of the PDUFA date — came through for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia.

Drugs being acquired include the two already marketed products Oncaspar for acute lymphoblastic leukemia and rights outside the United States to Onivyde for pancreatic cancer.

Today, medical science cures 90 % of children with acute lymphoblastic leukemia, so we don't need that useless Jesus who couldn't cure anybody.

JP Gibson, a 5 - year - old who was diagnosed with acute lymphoblastic leukemia in 2012, was signed to a one - day contract by the Utah Jazz.

SPENCER SARTIN wasdiagnosed with acute lymphoblastic leukemia in October 2004.

He remains a leader in supportive care and research in pediatric oncology, with a special focus on neuroblastoma, non-Hodgkin lymphoma, Ewing Sarcoma, acute lymphoblastic leukemia and brain tumors.

It has been noted that babies born via section are at a 23 % increased risk for this Lymphoblastic Leukemia.

According to new information in cancer research, there could be a new correlation between C - section delivery and Lymphoblastic Leukemia.

Grupp has offered CAR - T therapy to more than 150 children with late - stage acute lymphoblastic leukemia (ALL)-- and worries that because of supply limitations, he can't help more.

Current treatments for acute lymphoblastic leukemia (ALL), an aggressive form of blood cancer, include conventional chemotherapy drugs that inhibit DNA synthesis.

Acute lymphoblastic leukemia is most frequent in children, adolescents and young adults, and it has a five - year survival rate of over 90 %.

In this study, the two - pronged experimental treatment was given to mice that had acute lymphoblastic leukemia (ALL, a deadly blood cancer).

Scientists from Cincinnati Children's Hospital Medical Center report that their experimental combination treatment strategy — using a small molecular inhibitor along with chemotherapy — was particularly effective at stopping a stubborn leukemia called T - cell acute lymphoblastic leukemia, or T - ALL.

Called CAR - T cell immunotherapy (for chimeric antigen receptor T cell), one is for kids and young adults with B cell acute lymphoblastic leukemia, or ALL, approved in August (SN Online: 8/30/17).

EM: Lukas [Wartman, a doctor at Washington University] was dying of a second relapse of acute lymphoblastic leukemia.

An enzyme identified in Saccharomyces cerevisiae, commonly known as brewer's or baker's yeast, has passed in vitro trials, demonstrating its capacity to kill acute lymphoblastic leukemia (ALL) cells.

«Protein isolated from baker's yeast shows potential against leukemia cells: Researchers performed in vitro trials to test the effect of L - asparaginase on acute lymphoblastic leukemia cells and published the results in Scientific Reports.»

WASHINGTON — Immune cells engineered to hunt and destroy cancer cells may help some people with acute lymphoblastic leukemia (ALL) live much longer.

CAR T cell therapies have already shown tremendous promise for treating blood - based cancers, leading the Food and Drug Administration's Oncologic Drugs Advisory Committee to unanimously recommend a Novartis CAR T regimen named tisagenlecleucel for approval to treat pediatric B - cell acute lymphoblastic leukemia, in a landmark ruling in July 2017.

In PLAT - 02, the CAR T cells are reprogrammed to recognize and target the CD19 protein that is expressed by most precursor B acute lymphoblastic leukemia cells.

In a cover story set to appear in the journal Cancer Cell online June 8, researchers at NYU Langone and elsewhere report that they have successfully halted and reversed the growth of certain cancerous white blood cells at the center of T - cell acute lymphoblastic leukemia, or T - ALL, by stalling the action of a specific protein receptor found in abundance on the surface of T cells at the core of T - ALL.

However, genetic mutations in a gene called mixed lineage leukemia, or MLL, lead to an aggressive subtype of B - ALL known as MLL - rearranged, which is the most common type of acute lymphoblastic leukemia in infants.